Please ensure Javascript is enabled for purposes of website accessibility

Why Relypsa, Inc. Shares Crashed 15% Today

By Todd Campbell - Feb 25, 2016 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The risk of a capital raise to cover mounting expenses is weighing on the company.


What: Shares of Relypsa (RLYP) tumbled 15.14% today after the company reported fourth-quarter financials and revealed that it will need to raise cash.

So what: Relypsa is knee-deep in the launch of its first and only commercial drug, Veltassa. Last fall, Veltassa won Food and Drug Administration approval for use in patients suffering from hyperkalemia, or extraordinarily high levels of potassium in the blood.

So far, Relypsa reports that 1,229 scripts have been written for Veltassa, and while that's an OK start, the revenue being generated from Veltassa sales isn't going to be nearly enough to offset surging expenses associated with establishing a foothold in the market.

Last quarter, the company's revenue totaled only $12 million, yet its operating expenses jumped to $70.5 million from $27 million a year ago.

Now what: Relypsa isn't giving guidance for sales this year, but it does expect to spend between $275 million and $300 million this year and that amount is roughly the same as the $285 million in cash the company has on the books in February.

Absent a big uptick in revenue from Veltassa, the pace of expenses will require management to raise money. Unfortunately, a steep sell-off in the shares makes the most desirable source of capital -- an equity offering -- less palatable. Regardless, the company did sell shares to the public through an existing after-market offering and it can still raise $29.4 million via that offering.

Even so, that extra $29.4 million may not get the job done and that could mean another dilutive offering, a debt issue, or the sale of some of the company's rights to Veltassa in the U.S. is on the horizon.

Overall, the market for hyperkalemia drugs could be big enough to justify taking on a little risk. After all, industry watchers think that Veltassa could eventually have nine-figure sales potential. However, until investors get a bit more insight into the company's long-term cash plans and Veltassa sales ramp, it may be best to watch and wait. 


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Relypsa, Inc. Stock Quote
Relypsa, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.